Research programme: topical anti-infectives - Helix BioMedix

Drug Profile

Research programme: topical anti-infectives - Helix BioMedix

Alternative Names: HB 1148; HB 1275; HB 153; HB 97; HB-50; Lipohexapeptides - Helix BioMedix

Latest Information Update: 22 Feb 2010

Price : $50

At a glance

  • Originator Helix BioMedix
  • Class Biological peptides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Mycoses

Most Recent Events

  • 22 Feb 2010 Preclinical development is ongoing in USA
  • 29 Mar 2007 Helix BioMedix intends to license compounds from this programme outside of the US (http://www.helixbiomedix.com/wt/page/company/)
  • 21 Jan 2005 Helix BioMedix has offered Smith & Nephew a right of first offer to license certain rights to a number of wound-related indications for HB 50
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top